A5102010746- Cervical Cancer and HPV Research
- Statistical Methods in Clinical Trials
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Meta-analysis and systematic reviews
- Health Services Management and Policy
- Open Source Software Innovations
- Cardiovascular Function and Risk Factors
- Healthcare Systems and Challenges
- FinTech, Crowdfunding, Digital Finance
- Prenatal Screening and Diagnostics
- Pregnancy and preeclampsia studies
- Health and Medical Research Impacts
- Healthcare Policy and Management
- Cardiac Valve Diseases and Treatments
- School Health and Nursing Education
- Healthcare Quality and Management
- Big Data and Business Intelligence
- Endometrial and Cervical Cancer Treatments
- Heart Rate Variability and Autonomic Control
- Orthopaedic implants and arthroplasty
- Molecular Biology Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Health and Well-being Studies
PricewaterhouseCoopers (United States)
2023
Brain Tumour Charity
2011
The Royal Free Hospital
1968
University College London
1968
The potential efficacy of screening for trisomy 21 in the first trimester, using maternal serum markers α fetoprotein, free β human chorionic gonadotropin, unconjugated oestriol and pregnancy associated plasma protein A, was studied an unselected population women between seventh fourteenth week gestation. Using a combination fetoprotein 53% affected pregnancies could be identified at false positive rate 5%. Unconjugated A levels were lower cases 21, but their inclusion with other did not...
Poor cancer survival rates in the United Kingdom are often blamed on delayed medical care. A local audit of endometrial revealed a variety preventable delays. We surveyed practice South West England to see if this was an isolated or widespread problem.All 15 hospitals collected information prospectively from all women with over 3 months spring 2009.There were delays stages uterine pathway. Excluding extraneous cases, 52% waited more than month and 12% 6 their GP onset symptoms. Almost half...
Abstract The first biomarker-based cervical cancer screening test, p16/Ki-67 dual-stained cytology (DS), has been clinically validated and approved in the United States for triage of women being screened who test positive high-risk human papillomavirus (hrHPV). primary aim this work is to evaluate cost-effectiveness DS after co-testing findings non-16/18 HPV types atypical squamous cells undetermined significance or low-grade intraepithelial lesions cytology. A payer-perspective Markov...
<p>Supplemental Table S1 shows the unpublished data from IMPACT clinical trial referenced in for model inputs</p>
<p>Supplemental Table S3 shows the procedure codes, CMS fee schedule payments, and usage information used to develop cost inputs for screening visits, tests, procedures</p>
<p>Supplemental Table S1 shows the unpublished data from IMPACT clinical trial referenced in for model inputs</p>
<p>Supplemental Table S2 shows the distribution of patient attributes in prevalent US population women eligible for cervical cancer screening</p>
<p>Supplemental Table S3 shows the procedure codes, CMS fee schedule payments, and usage information used to develop cost inputs for screening visits, tests, procedures</p>
<p>Supplemental Table S2 shows the distribution of patient attributes in prevalent US population women eligible for cervical cancer screening</p>
<p>Supplemental Table S4 shows the top five most influential inputs based on one-way sensitivity analyses each of mean change in costs, QALYs, and life-years with addition DS reflex to common co-testing screening strategies</p>
<p>Supplemental Table S4 shows the top five most influential inputs based on one-way sensitivity analyses each of mean change in costs, QALYs, and life-years with addition DS reflex to common co-testing screening strategies</p>
<p>Supplemental Figure S1 shows tornado diagrams of range results observed in the one-way sensitivity analyses</p>
<p>Supplemental Figure S1 shows tornado diagrams of range results observed in the one-way sensitivity analyses</p>
<div>Abstract<p>The first biomarker-based cervical cancer screening test, p16/Ki-67 dual-stained cytology (DS), has been clinically validated and approved in the United States for triage of women being screened who test positive high-risk human papillomavirus (hrHPV). The primary aim this work is to evaluate cost-effectiveness DS after co-testing findings non-16/18 HPV types atypical squamous cells undetermined significance (ASCUS) or low-grade intraepithelial lesions (LSIL)...
<p>Supplemental Figure S2 shows the proportion of PSA simulations that were cost-effective at varying willingness-to-pay thresholds</p>
<p>Supplemental Figure S2 shows the proportion of PSA simulations that were cost-effective at varying willingness-to-pay thresholds</p>
<p>Supplemental Table S1 shows the unpublished data from IMPACT clinical trial referenced in for model inputs</p>